Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Arbutus Biopharma Corporation Common Stock (ABUS)

Pharmaceutical Preparations

http://www.arbutusbio.com

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

701 VETERANS CIRCLE
WARMINSTER, PA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/26/2007

Market Cap

701,325,130

Shares Outstanding

167,700,000

Weighted SO

167,695,247

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

VBIV --.--%

ADMA --.--%

ADAP --.--%

AFMD --.--%

CRVS --.--%

Beta

1.9560

Last Div

0.0000

Range

1.69-3.98

Chg

-0.0350

Avg Vol

1033701

Mkt Cap

701325130

Exch

NASDAQ

Country

US

Phone

267 469 0914

DCF Diff

6.6431

DCF

-2.9281

Div Yield

0.0000

P/S

69.7073

EV Multiple

-7.9202

P/FV

5.7048

Div Yield %

0.0000

P/E

-9.0622

PEG

-0.3010

Payout

0.0000

Current Ratio

6.5599

Quick Ratio

6.8358

Cash Ratio

2.7788

DSO

74.9881

DIO

-1581.2439

Op Cycle

-1506.2558

DPO

672.6755

CCC

-2178.9313

Gross Margin

0.8570

Op Margin

-8.2132

Pretax Margin

-7.6620

Net Margin

-7.6620

Eff Tax Rate

-0.0091

ROA

-0.4817

ROE

-0.6668

ROCE

-0.6012

NI/EBT

1.0000

EBT/EBIT

0.9329

EBIT/Rev

-8.2132

Debt Ratio

0.0394

D/E

0.0515

LT Debt/Cap

0.0457

Total Debt/Cap

0.0490

Int Coverage

-1087.2763

CF/Debt

-11.3386

Equity Multi

1.3070

Rec Turnover

4.8674

Pay Turnover

0.5426

Inv Turnover

-0.2308

FA Turnover

1.8997

Asset Turnover

0.0629

OCF/Share

-0.3806

FCF/Share

-0.3812

Cash/Share

0.7551

OCF/Sales

-7.1136

FCF/OCF

1.0016

CF Coverage

-11.3386

ST Coverage

-157.9900

CapEx Coverage

-628.0192

Div&CapEx Cov

-628.0192

P/BV

5.7048

P/B

5.7048

P/S

69.7073

P/E

-9.0622

P/FCF

-9.7836

P/OCF

-9.7608

P/CF

-9.7608

PEG

-0.3010

P/S

69.7073

EV Multiple

-7.9202

P/FV

5.7048

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 05, 06:30 Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure GlobeNewswire Inc. May 22, 06:00 Arbutus to Present Imdusiran Data at EASL Congress 2024 GlobeNewswire Inc. Jan 08, 07:30 Arbutus Announces 2024 Corporate Objectives and Provides Financial Update GlobeNewswire Inc. Nov 08, 07:30 Arbutus to Present at Jefferies London Healthcare Conference GlobeNewswire Inc. Nov 07, 07:30 Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Revenue Product Segmentation